×
News Home

What is Wall Street's Target Price for Adverum Biotechnologies Inc (ADVM) Stock Thursday?

Thursday, June 23, 2022 01:49 PM | InvestorsObserver Analysts
What is Wall Street's Target Price for Adverum Biotechnologies Inc (ADVM) Stock Thursday?

Wall Street is positive on Adverum Biotechnologies Inc (ADVM). On average, analysts give ADVM a Buy rating. The average price target is $3, which means analysts expect the stock to rise by 188.46% over the next twelve months. That average ranking earns ADVM an Analyst Rating of 21, which is better than 21% of stocks based on data compiled by InvestorsObserver.

Overall Score - 3.7
Wall Street analysts are rating ADVM a Buy today. Find out what this means to you and get the rest of the rankings on ADVM!

Why are Analyst Ratings Important?

Analysts know the inner workings of the companies they follow better than anyone but the companies’ management. You can learn a lot about a company from studying the financial statements, but analysts ask questions on conference calls and understand the intricacies of each of the businesses they cover. Analysts understand how bad weather in one part of the world can disrupt supply chains, or disrupt shopping patterns. This lets traders make decisions before a quarterly report that could be worse than expected. InvestorsObserver aggregates the ratings of all the analysts covering a given stock, takes the average of those ratings and then percentile ranks the averages. That provides a level of granularity that is significantly better than just the three levels provided by traditional buy/hold/sell ratings.

What's Happening With Adverum Biotechnologies Inc Stock Today?

Adverum Biotechnologies Inc (ADVM) stock is trading at $1.04 as of 1:45 PM on Thursday, Jun 23, a decline of -$0.02, or -2.12% from the previous closing price of $1.06. The stock has traded between $1.02 and $1.05 so far today. Volume today is light. So far 702,255 shares have traded compared to average volume of 1,070,146 shares. Click Here to get the full Stock Report for Adverum Biotechnologies Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App